Literature DB >> 24416583

Volumetric-modulated arc therapy with RapidArc(®): An evaluation of treatment delivery efficiency.

Beatriz E Amendola1, Marco Amendola1, Naipy Perez1, Alejandro Iglesias1, Xiaodong Wu1.   

Abstract

AIM/
BACKGROUND: To evaluate how the use of volumetric-modulated arc therapy (VMAT) with RapidArc(®) can improve treatment delivery efficiency based on the analysis of the beam-on times and monitor units (MU) needed to deliver therapy for multiple clinical applications in a large patient population.
MATERIALS AND METHODS: A total of 898 treatment courses were delivered in 745 patients treated from October 2008 to March 2013 using RapidArc® treatment plans generated in Eclipse™ TPS. All patients were treated with curative or palliative intent using different techniques including conventional fractionation (83%) and radiosurgery or SBRT (17%), depending on the clinical indications. Treatment delivery was evaluated based on measured beam-on time and recorded MU values delivered on a Varian Trilogy™ linear accelerator.
RESULTS: For conventional fractionation treatments using RapidArc®, the delivery times ranged from 38 s to 4 min and 40 s (average 2 min and 6 s). For radiosurgical treatments the delivery times ranged from 1 min and 42 s to 9 min and 22 s (average 4 min and 4 s). The average number of MU per Gy was 301 for the entire group, with 285 for the conventional group and 317 for the radiosurgical group.
CONCLUSIONS: In this study with a large heterogeneous population, treatments using RapidArc® were delivered with substantially less beam-on time and fewer MUs than conventional fractionation. This was highly advantageous, increasing flexibility of the scheduling allowing treatment of radiosurgery patients during the regular daily work schedule. Additionally, reduction of leakage radiation dose was achieved.

Entities:  

Keywords:  IMRT; RapidArc; SBRT; SRS; Treatment Planning software; VMAT

Year:  2013        PMID: 24416583      PMCID: PMC3863300          DOI: 10.1016/j.rpor.2013.07.005

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  8 in total

Review 1.  Intensity modulated radiation therapy: a clinical review.

Authors:  C Nutting; D P Dearnaley; S Webb
Journal:  Br J Radiol       Date:  2000-05       Impact factor: 3.039

Review 2.  Volumetric modulated arc therapy: a review of current literature and clinical use in practice.

Authors:  M Teoh; C H Clark; K Wood; S Whitaker; A Nisbet
Journal:  Br J Radiol       Date:  2011-11       Impact factor: 3.039

3.  Stereotactic radiotherapy for peripheral lung tumors: a comparison of volumetric modulated arc therapy with 3 other delivery techniques.

Authors:  Chin Loon Ong; Wilko F A R Verbakel; Johan P Cuijpers; Ben J Slotman; Frank J Lagerwaard; Suresh Senan
Journal:  Radiother Oncol       Date:  2010-11-11       Impact factor: 6.280

4.  Volumetric modulated arc therapy: IMRT in a single gantry arc.

Authors:  Karl Otto
Journal:  Med Phys       Date:  2008-01       Impact factor: 4.071

5.  Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes.

Authors:  Sua Yoo; Q Jackie Wu; W Robert Lee; Fang-Fang Yin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-08       Impact factor: 7.038

6.  The use of RapidArc volumetric-modulated arc therapy to deliver stereotactic radiosurgery and stereotactic body radiotherapy to intracranial and extracranial targets.

Authors:  Dante E Roa; Daniel C Schiffner; Juying Zhang; Salam N Dietrich; Jeffrey V Kuo; Jason Wong; Nilam S Ramsinghani; Muthana S A L Al-Ghazi
Journal:  Med Dosim       Date:  2012-02-24       Impact factor: 1.482

7.  Dosimetry Comparison between Volumetric Modulated Arc Therapy with Rapid Arcand Fixed Field Dynamic IMRT for Local-Regionally Advanced Nasopharyngeal Carcinoma.

Authors:  Bao-Min Zheng; Xiao-Xia Dong; Hao Wu; Shu-Kui Han; Yan Sun
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087

8.  Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation.

Authors:  Michael K M Kam; Ricky M C Chau; Joyce Suen; Peter H K Choi; Peter M L Teo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

  8 in total
  7 in total

1.  Analyzing the performance of ArcCHECK diode array detector for VMAT plan.

Authors:  Rajesh Thiyagarajan; Arunai Nambiraj; Sujit Nath Sinha; Girigesh Yadav; Ashok Kumar; Vikraman Subramani
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-02

2.  Is dose escalation achievable for esophageal carcinoma?

Authors:  Laure Vieillevigne; Marie Vidal; Françoise Izar; Michel Rives
Journal:  Rep Pract Oncol Radiother       Date:  2015-01-05

3.  Radiotherapy infrastructure and human resources in Switzerland : Present status and projected computations for 2020.

Authors:  Niloy Ranjan Datta; Shaka Khan; Dietmar Marder; Daniel Zwahlen; Stephan Bodis
Journal:  Strahlenther Onkol       Date:  2016-07-25       Impact factor: 3.621

4.  Volumetric modulated arc therapy vs. c-IMRT for the treatment of upper thoracic esophageal cancer.

Authors:  Wu-Zhe Zhang; Tian-Tian Zhai; Jia-Yang Lu; Jian-Zhou Chen; Zhi-Jian Chen; De-Rui Li; Chuang-Zhen Chen
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

5.  Stereotactic ablative radiosurgery for locally advanced or recurrent skull base malignancies with prior external beam radiation therapy.

Authors:  Karen M Xu; Kimmen Quan; David A Clump; Robert L Ferris; Dwight E Heron
Journal:  Front Oncol       Date:  2015-03-17       Impact factor: 6.244

6.  Dosimetric effect of limited aperture multileaf collimator on VMAT plan quality: A study of prostate and head-and-neck cancers.

Authors:  Ghulam Murtaza; Shahid Mehmood; Shahid Rasul; Imran Murtaza; Ehsan Ullah Khan
Journal:  Rep Pract Oncol Radiother       Date:  2018-03-21

7.  Dosimetric comparison between cone/Iris-based and InCise MLC-based CyberKnife plans for single and multiple brain metastases.

Authors:  Si Young Jang; Ron Lalonde; Cihat Ozhasoglu; Steven Burton; Dwight Heron; M Saiful Huq
Journal:  J Appl Clin Med Phys       Date:  2016-09-08       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.